|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
|
HUE069586T2
(hu)
|
2010-10-01 |
2025-03-28 |
Modernatx Inc |
Módosított nukleozidok, nukleotidok és nukleinsavak, valamint ezek felhasználása
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
HK1199736A1
(en)
*
|
2011-08-26 |
2015-07-17 |
箭头研究公司 |
Poly(vinyl ester) polymers for in vivo nucleic acid delivery
|
|
EP3453761A1
(en)
|
2011-08-29 |
2019-03-13 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
DK3682905T3
(da)
|
2011-10-03 |
2022-02-28 |
Modernatx Inc |
Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
|
|
HRP20220717T1
(hr)
|
2011-12-16 |
2022-07-22 |
Modernatx, Inc. |
Modificirani pripravci mrna
|
|
US8796405B2
(en)
*
|
2012-01-18 |
2014-08-05 |
Wisconsin Alumni Research Foundation |
Degradable polycations derived from amino acid vinyl esters
|
|
JP6189415B2
(ja)
|
2012-04-02 |
2017-08-30 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
JP2015515530A
(ja)
*
|
2012-04-18 |
2015-05-28 |
アローヘッド リサーチ コーポレイション |
インビボ核酸送達のためのポリ（アクリラート）ポリマー
|
|
EP2922554B1
(en)
|
2012-11-26 |
2022-02-23 |
ModernaTX, Inc. |
Terminally modified rna
|
|
SG11201506805QA
(en)
|
2013-02-28 |
2015-09-29 |
Arrowhead Res Corp |
Organic compositions to treat epas1-related diseases
|
|
KR20160014584A
(ko)
|
2013-03-13 |
2016-02-11 |
코어 파마슈티칼스 디벨롭먼트 컴퍼니 |
염증 치료용 면역-변형된 입자
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
IL296543B2
(en)
|
2013-05-01 |
2025-02-01 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating HBV and TTR expression
|
|
CN105451743B
(zh)
|
2013-08-07 |
2019-11-19 |
箭头研究公司 |
用于在活体中递送RNAi触发子至肿瘤细胞的聚偶联物
|
|
JP2016530294A
(ja)
|
2013-09-03 |
2016-09-29 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
キメラポリヌクレオチド
|
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
EP3137476B1
(en)
|
2014-04-28 |
2019-10-09 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
|
KR20200102553A
(ko)
|
2014-05-01 |
2020-08-31 |
아이오니스 파마수티컬즈, 인코포레이티드 |
성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법
|
|
UA121656C2
(uk)
|
2014-05-01 |
2020-07-10 |
Айоніс Фармасьютикалз, Інк. |
Олігомерна сполука та спосіб лікування захворювання, пов'язаного з порушенням регуляції альтернативного шляху комплементу
|
|
EP4534092A3
(en)
|
2014-05-01 |
2025-07-02 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating pkk expression
|
|
BR122020024443B1
(pt)
|
2014-05-01 |
2022-02-22 |
Ionis Pharmaceuticals, Inc |
Composto e composição farmacêutica para modulação da expressão de angptl3
|
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
|
|
CA2955250A1
(en)
|
2014-07-16 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
WO2016014846A1
(en)
|
2014-07-23 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
BR112017004056A2
(pt)
|
2014-09-12 |
2017-12-05 |
Biogen Ma Inc |
composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
|
|
CA2984498C
(en)
|
2015-05-29 |
2024-01-02 |
Arrowhead Pharmaceuticals, Inc. |
Compositions and methods for inhibiting gene expression of hif2alpha
|
|
BR112017028194B1
(pt)
|
2015-07-10 |
2023-03-14 |
Ionis Pharmaceuticals, Inc |
Composto oligomérico modulador de diaciglicerol aciltransferase 2 (dgat2), composição, e seus usos
|
|
CN108271387B
(zh)
|
2015-08-07 |
2023-06-27 |
箭头药业股份有限公司 |
乙型肝炎病毒感染的RNAi疗法
|
|
CN108513588A
(zh)
|
2015-09-24 |
2018-09-07 |
Ionis制药公司 |
Kras表达的调节剂
|
|
JOP20210043A1
(ar)
|
2015-10-01 |
2017-06-16 |
Arrowhead Pharmaceuticals Inc |
تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
|
|
BR112018008102A2
(pt)
|
2015-10-22 |
2018-11-06 |
Modernatx Inc |
vacina de vírus sincicial respiratório
|
|
EA201890999A1
(ru)
|
2015-10-22 |
2018-12-28 |
МОДЕРНАТиЭкс, ИНК. |
Вакцина против вируса простого герпеса
|
|
EA201891001A1
(ru)
|
2015-10-22 |
2018-11-30 |
МОДЕРНАТиЭкс, ИНК. |
Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
|
|
WO2017070613A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
KR20180096591A
(ko)
|
2015-10-22 |
2018-08-29 |
모더나티엑스, 인크. |
광범위 인플루엔자 바이러스 백신
|
|
MD3718565T2
(ro)
|
2015-10-22 |
2022-09-30 |
Modernatx Inc |
Vaccinuri împotriva virusului respirator
|
|
JP7486920B2
(ja)
|
2015-11-06 |
2024-05-20 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
アポリポタンパク質（ａ）発現の調節
|
|
LT4119569T
(lt)
|
2015-11-06 |
2024-09-25 |
Ionis Pharmaceuticals, Inc. |
Konjuguoti priešprasmiai junginiai, skirti panaudoti terapijoje
|
|
PT3394093T
(pt)
|
2015-12-23 |
2022-05-30 |
Modernatx Inc |
Métodos de utilização de polinucleotídeos que codificam ligandos ox40
|
|
US20190241658A1
(en)
|
2016-01-10 |
2019-08-08 |
Modernatx, Inc. |
Therapeutic mRNAs encoding anti CTLA-4 antibodies
|
|
IL296377A
(en)
|
2016-03-07 |
2022-11-01 |
Arrowhead Pharmaceuticals Inc |
Targeting ligands for therapeutic compounds and uses of same
|
|
CA3023764A1
(en)
|
2016-06-06 |
2017-12-14 |
Arrowhead Pharmaceuticals, Inc. |
5'-cyclo-phosphonate modified nucleotides
|
|
MX2019000619A
(es)
|
2016-07-15 |
2019-08-01 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para la modulacion de smn2.
|
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
|
CN116942841A
(zh)
|
2016-09-02 |
2023-10-27 |
箭头药业股份有限公司 |
靶向配体
|
|
WO2018067900A1
(en)
|
2016-10-06 |
2018-04-12 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
|
US10450565B2
(en)
|
2017-01-10 |
2019-10-22 |
Arrowhead Pharmaceuticals, Inc. |
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
|
|
CA3048661A1
(en)
|
2017-01-30 |
2018-08-02 |
Arrowhead Pharmaceuticals Inc. |
Compositions and methods for inhibition of factor xii gene expression
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
|
JP2020526192A
(ja)
|
2017-07-06 |
2020-08-31 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
アルファ−ＥＮａＣの発現を阻害するためのＲＮＡｉ剤、および使用方法
|
|
JP7275111B2
(ja)
|
2017-08-31 |
2023-05-17 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子の生成方法
|
|
SG11201912178VA
(en)
|
2017-09-11 |
2020-01-30 |
Arrowhead Pharmaceuticals Inc |
Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
|
|
KR20250004009A
(ko)
|
2017-09-14 |
2025-01-07 |
애로우헤드 파마슈티컬스 인코포레이티드 |
안지오포이에틴-유사 3 (ANGPTL3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물, 및 사용 방법
|
|
CA3079413A1
(en)
|
2017-10-17 |
2019-04-25 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents and compositions for inhibiting expression of asialoglycoprotein receptor 1
|
|
MX2020007369A
(es)
|
2018-01-15 |
2020-10-28 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion de dnm2.
|
|
AU2019218987B2
(en)
|
2018-02-12 |
2025-04-24 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
JOP20200280A1
(ar)
|
2018-05-09 |
2020-11-05 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير الوراثي عن fxi
|
|
EP3823725A4
(en)
|
2018-07-17 |
2023-05-10 |
Aronora, Inc. |
METHODS FOR SAFELY REDUCING THROMBOPOIETIN
|
|
WO2020033748A1
(en)
|
2018-08-08 |
2020-02-13 |
Arcturus Therapeutics, Inc. |
Compositions and agents against nonalcoholic steatohepatitis
|
|
TWI869213B
(zh)
|
2018-09-19 |
2025-01-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
JP7394137B2
(ja)
|
2018-12-21 |
2023-12-07 |
アイオニス・ファーマシューティカルズ・インコーポレイテッド |
Ｈｓｄ１７ｂ１３発現のモジュレータ
|
|
CA3120580A1
(en)
|
2019-01-09 |
2020-07-16 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
|
|
KR20210130736A
(ko)
|
2019-02-07 |
2021-11-01 |
애로우헤드 파마슈티컬스 인코포레이티드 |
B형 간염 바이러스 감염에 대한 RNAi 작용제
|
|
US20220305107A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
|
|
JP2022536945A
(ja)
|
2019-06-18 |
2022-08-22 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
Ｂ型肝炎ウイルス（ＨＢＶ）ワクチンおよびＨＢＶを標的化するＲＮＡｉの組合せ
|
|
EP4045062A1
(en)
|
2019-10-14 |
2022-08-24 |
Astrazeneca AB |
Modulators of pnpla3 expression
|
|
TW202517787A
(zh)
|
2020-02-28 |
2025-05-01 |
美商Ionis製藥公司 |
用於調節smn2之化合物及方法
|
|
AU2021242321B2
(en)
|
2020-03-26 |
2025-09-04 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use
|
|
CN115916219A
(zh)
|
2020-04-21 |
2023-04-04 |
旗舰创业股份有限公司 |
双官能分子及其使用方法
|
|
MX2023002883A
(es)
|
2020-09-11 |
2023-03-31 |
Arrowhead Pharmaceuticals Inc |
Conjugados lipidicos para el transporte de agentes terapeuticos.
|
|
CA3189077A1
(en)
|
2020-09-11 |
2022-03-17 |
Xiaokai Li |
Skeletal muscle delivery platforms and methods of use
|
|
AU2021342155A1
(en)
|
2020-09-11 |
2023-04-13 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
|
|
EP4488371A3
(en)
|
2020-11-18 |
2025-04-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
|
EP4319765A1
(en)
|
2021-04-08 |
2024-02-14 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
|
|
EP4326334A1
(en)
|
2021-04-23 |
2024-02-28 |
GanNA Bio, Inc. |
Glycan modified nucleic acids, methods of preparation, and therapeutic uses
|
|
AU2022280863A1
(en)
|
2021-05-28 |
2023-11-30 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of mucin 5ac (muc5ac), compositions thereof, and methods of use
|
|
US11549112B1
(en)
|
2021-06-21 |
2023-01-10 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
|
|
WO2023056440A1
(en)
|
2021-10-01 |
2023-04-06 |
Adarx Pharmaceuticals, Inc. |
Prekallikrein-modulating compositions and methods of use thereof
|
|
JP2025508467A
(ja)
|
2022-02-24 |
2025-03-26 |
アイオー バイオテック エーピーエス |
癌治療のヌクレオチド送達
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
CN119730859A
(zh)
|
2022-06-15 |
2025-03-28 |
箭头药业股份有限公司 |
用于抑制超氧化物歧化酶1(SOD1)表达的RNAi剂、其组合物及使用方法
|
|
WO2024197017A2
(en)
|
2023-03-21 |
2024-09-26 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of complement factor b (cfb) pharmaceutical compositions thereof, and methods of use
|
|
CN121285630A
(zh)
|
2023-04-20 |
2026-01-06 |
阿达尔克斯制药有限公司 |
Mapt调节组合物及其使用方法
|
|
AU2024273075A1
(en)
|
2023-05-12 |
2025-11-20 |
Adarx Pharmaceuticals, Inc. |
Nmda ligand conjugated compounds and uses thereof
|
|
WO2024249328A2
(en)
|
2023-05-26 |
2024-12-05 |
Adarx Pharmaceuticals, Inc. |
Sod1-modulating compositions and methods of use thereof
|
|
WO2024263694A1
(en)
|
2023-06-20 |
2024-12-26 |
Adarx Pharmaceuticals, Inc. |
Lrrk2-modulating compositions and methods of use thereof
|
|
WO2025049773A1
(en)
|
2023-08-30 |
2025-03-06 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of inhibin subunit beta e (inhbe), pharmaceutical compositions thereof, and methods of use
|
|
EP4520345A1
(en)
|
2023-09-06 |
2025-03-12 |
Myneo Nv |
Product
|
|
WO2025072748A2
(en)
|
2023-09-29 |
2025-04-03 |
Insitro, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease
|
|
US12442002B2
(en)
|
2023-12-20 |
2025-10-14 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), compositions thereof, and methods of use
|
|
WO2025196505A2
(en)
|
2024-03-22 |
2025-09-25 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for inhibiting cytochrome p450 family 7 subfamily a member 1 (cyp7a1) expression
|
|
US20250333742A1
(en)
|
2024-04-25 |
2025-10-30 |
Insitro, Inc. |
Compositions and methods for treating metabolic dysfunction-associated steatotic liver disease
|
|
WO2025265013A2
(en)
|
2024-06-20 |
2025-12-26 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of huntingtin (htt), compositions thereof, and methods of use
|